It is a popular tourist destination as part of the US, but what about consuming cannabis there?
Over 5 million people travel to Puerto Rico each year, the island territory of the US is popular with tourists. Beaches, outdoor adventures, good food and sun are always a popular draw and it is considered a safe and easy destinations. Millions of American’s have visited, but as the US embraces marijuana, what about US territory Puerto Rico and cannabis?
Puerto Rico became a territory of the United States as a result of the Spanish-American War in 1898. In 1898, the United States went to war with Spain and invaded their colony Puerto Rico on July 25, 1898. It has been under Spanish rule for over 400 years.War ended with the signing of the Treaty of Paris with Spain ceding Puerto Rico to the United States, along with other territories like Guam. After the war, Puerto Rico came under direct U.S. military rule for about two years. In 1900, the U.S. Congress passed the Foraker Act, which established a civilian government for Puerto Rico and officially designated it as an “unincorporated territory” belonging to the United States. It has some benefits of the US, but not a formal voice in the Congress.
The locals have nothing against fun, the national drink of Puerto Rico is the Pina Coloda. Made with local rum, coconut cream, and pineapple juice. It’s often made without rum so that everyone can enjoy it. Also, 85% of the population identifies as Catholic, a faith that doesn’t mind some wine.
Like the mainland US, Puerto Rico enacted legislation banning cannabis in 1932, making it illegal to plant, import, purchase, or sell marijuana. The prohibition remained in place for decades, with attempts at decriminalization failing to gain traction. In 2013, a proposal to decriminalize cannabis was met with significant public opposition, with 70% of those surveyed against the idea.
A major shift occurred in 2015 when Governor Alejandro Garcia Padilla signed an executive order permitting the use of medical cannabis. This was followed in 2017 by the passage of Act 42-2017, officially legalizing cannabis for medicinal purposes in Puerto Rico.The medical cannabis program established regulations for:
Licensing of dispensaries, cultivators, processors, and caregivers
Safety protocols including product testing and labeling requirements
Taxation of cannabis sales to fund social programs and education initiatives
While smoking cannabis remains prohibited, other forms of consumption are permitted for approved medical conditions. Recreational use of cannabis in Puerto Rico remains illegal. Possession is considered a crime with some type of punishment.
However, in 2015 the governor advised judges not to imprison defendants caught with less than 6 grams of cannabis, indicating some leniency for small amounts. Despite its illegal status, marijuana remains one of the most commonly abused illicit drugs in Puerto Rico
Tariffs are the word of the day – but marijuana consumers need to be ready to see a change also.
From apples to automobiles, hundreds of industries are trying to figure out the new tariffs. What is clear is prices are going up on a random amount of things. But, why is a surprise, is cannabis consumers are being hit by the tariffs also. Although cannabis itself cannot be imported or exported due to federal restrictions, the industry heavily relies on international suppliers for key components like vaporizer hardware, packaging, and cultivation equipment.
For instance, products sourced from China now face cumulative tariffs as high as 45%, including a 10% increase imposed in February 2025. Similarly, imports from Canada and Mexico face 25% tariffs. These measures have particularly affected items like vape cartridges, batteries, and specialized packaging materials, which are difficult to source domestically at competitive prices. As a result, many cannabis companies are passing these increased costs down the supply chain to consumer
The financial burden of these tariffs is substantial. Analysts estimate that most cannabis businesses lack the margin flexibility to absorb a 10%-15% cost increase. This has led to higher retail prices for products like pre-rolls and vaporizers, potentially pushing consumers toward cheaper, unregulated black-market alternatives. Such a shift raises concerns about product safety and could undermine the legal market’s growth.
Additionally, the tariffs have caused stock prices of major cannabis companies like Tilray Brands and Canopy Growth to decline by 5%-10%, reflecting investor concerns over profitability.Smaller businesses, already constrained by high taxes and limited banking access, are particularly vulnerable to these economic pressures.
Efforts to mitigate tariff-related expenses include exploring alternative manufacturing locations in countries like Malaysia or India. However, transitioning production is complex and time-consuming due to logistical hurdles and regulatory compliance requirements. Domestic production is another option but often comes with higher costs and limited capacity.
Packaging regulations in many states exacerbate the situation by requiring child-resistant designs, further limiting affordable domestic alternatives. Some companies are exploring sustainable packaging solutions as a long-term strategy to reduce dependence on volatile international markets.
The ongoing trade tensions show no signs of easing under Trump’s administration, leaving cannabis businesses with little choice but to adapt quickly. Strategies such as diversifying suppliers, investing in automation, and innovating with local materials may help companies weather the storm. However, without significant policy shifts or financial support mechanisms, the industry faces a challenging road ahead.
There is a buzz about sore throats today. While they are most common in colder months, spring allergies bring the pain also. This is often due to postnasal drip, which is when mucus from the nose and sinuses drains down the back of the throat, causing irritation and a scratchy feeling. Overuse of the voice, like talking loudly or singing for long periods, can tire out and strain the muscles in your throat, causing them to feel sore. The good news is cannabis can help a sore throat.
For those seeking natural alternatives to manage cold symptoms, cannabis is emerging as a promising option for throat irritation. Increasing research at medical center specifically targeting sore throats shows early insights. The data suggests cannabinoids and terpenes could offer symptom relief through their unique properties.
Photo by Esther Kelleter / EyeEm/Getty Images
Cannabis contains compounds like THC and CBD, which studies indicate possess anti-inflammatory properties that may reduce throat swelling and irritation. Terpenes such as eucalyptol—found in some strains—are traditionally associated with decongestant effects, potentially easing respiratory discomfort. These components work synergistically to calm inflamed tissues, though their direct impact on sore throats requires further clinical validation.
Smoking cannabis while ill remains controversial due to potential throat irritation from heat and smoke. Instead, experts recommend gentler options:
Edibles/lozenges: THC or CBD-infused products bypass inhalation, delivering localized relief without aggravating the throat.
Cannabis tea: Warm beverages with cannabis extracts may soothe scratchy throats while providing hydration.
Beyond direct throat relief, cannabis may improve overall wellness during illness. THC’s appetite-stimulating properties can combat reduced hunger, while its relaxing effects might promote restorative sleep. CBD’s muscle-relaxing qualities could help alleviate the body aches often accompanying colds.
While preliminary findings are encouraging, users should consult healthcare providers before combining cannabis with conventional cold medications due to potential interactions. Starting with low-dose CBD products may offer benefits without psychoactive effects. As legalization expands, more targeted research is expected to clarify cannabis’s role in respiratory health.
Innovative cannabis formulations—from throat-calming lozenges to anti-inflammatory teas—are redefining how we approach minor ailments. For those navigating cold season, these plant-based solutions present a compelling fusion of traditional herbal wisdom and modern cannabinoid science
Part of the cannabis industry supported the new president, betting he was going to move and move quickly on cannabis – the White House finally commented.
The cannabis industry has been a boon for consumers, medical patients, veterans and legal states, but for the thousands of mom and pop businesses is has been a roller coaster. With a huge demand, it would seem to be easy money, but the federal, tax, and banking restrictions have made it difficult to grow and expand. Part of the industry were all for the new administration assuming they would support positive change, but many in the new cabinet and the House Speaker Mike Johnson are foes. Now the White House finally comments on marijuana industry…and it doesn’t show a clear path.
The administration’s current stance on marijuana reform is marked by inaction, despite campaign promises and earlier signals of support for cannabis-related reforms. A White House official recently confirmed that “no action is being considered at this time” regarding marijuana policy, leaving advocates and industry stakeholders uncertain about the administration’s priorities.
During his campaign, the resident expressed support for rescheduling marijuana under the Controlled Substances Act (CSA), which would move it from Schedule I to Schedule III, easing restrictions on medical use and enabling cannabis businesses to access banking and tax benefits. However, since taking office, no concrete steps have been taken to advance this initiative. A DEA hearing on rescheduling, initially planned for January 2025, was postponed due to procedural appeals and remains unscheduled.
The president has also voiced support for state autonomy in cannabis policy and endorsed state-level legalization initiatives, such as Florida’s failed 2024 ballot measure for recreational marijuana. While this reflects a more favorable stance compared to his first term, his administration has yet to prioritize federal reforms like the SAFE Banking Act, which would facilitate banking services for cannabis businesses. Efforts to include such measures in a government funding bill late last year were unsuccessful.
The delay in federal action has significant implications for the cannabis industry. Rescheduling marijuana could alleviate financial burdens by eliminating restrictions under IRS Code Section 280E and promoting medical research. However, the stalled process leaves businesses navigating regulatory uncertainties and limited financial access.
While stakeholders continue lobbying for reform, the administration appears focused on other priorities such as immigration and foreign policy. Advocates hope the President will leverage his influence to advance cannabis reform, but for now, the issue remains sidelined. Until then the industry struggles and waits.